<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547117</url>
  </required_header>
  <id_info>
    <org_study_id>111261</org_study_id>
    <secondary_id>R01HL102387</secondary_id>
    <nct_id>NCT01547117</nct_id>
  </id_info>
  <brief_title>Dietary Salt in Postural Tachycardia Syndrome</brief_title>
  <official_title>Dietary Salt in Postural Tachycardia Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with POTS may not adequately expand their plasma volume in response to a high-sodium&#xD;
      (Na+) diet. Mechanisms involved in the regulation of plasma volume, such as the&#xD;
      renin-angiotensin-aldosterone system and renal dopamine, may be impaired in POTS and may&#xD;
      respond inappropriately to changes in dietary sodium.The purpose of this study is to&#xD;
      determine (1) whether a high dietary sodium level appropriately expands plasma volume in&#xD;
      POTS; (2) whether plasma renin activity and aldosterone are modified appropriately by changes&#xD;
      in dietary sodium in POTS; and (3) whether patients with POTS have improvements in their&#xD;
      orthostatic tachycardia and symptoms as a result of a high dietary sodium level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Day 1&#xD;
&#xD;
        -  Start 150 milliequivalents (mEq) Na+/day diet (POTS patients as inpatients; healthy&#xD;
           control subjects with clinical research center (CRC)- provided outpatient diet)&#xD;
&#xD;
        -  Start a 24h urine collection (for Na+, K+, Cr, fractionated catecholamines)&#xD;
&#xD;
        -  Blood work&#xD;
&#xD;
        -  Blood volume - carbon monoxide rebreathing&#xD;
&#xD;
      Study Day 2&#xD;
&#xD;
        -  Complete 24h urine&#xD;
&#xD;
        -  Start STUDY DIET (10 mEq Na+/day or 300 mEq Na+/day in a random order) after 3 meals of&#xD;
           150 mEq Na+/day are complete; water ad lib&#xD;
&#xD;
      Study Day 3 - 5&#xD;
&#xD;
        -  Continue STUDY DIET; water ad lib&#xD;
&#xD;
        -  On Day 5, a 24 hr holter combined ECG monitor will be placed on the subjects.&#xD;
&#xD;
      Study Day 6&#xD;
&#xD;
        -  Continue STUDY DIET; water ad lib&#xD;
&#xD;
        -  Remove 24h Holter combined ECG monitor and BP monitor from subject&#xD;
&#xD;
        -  Start a 24h urine collection (for Na+, K+, Cr, fractionated catecholamines)&#xD;
&#xD;
        -  Complete questionnaires&#xD;
&#xD;
        -  Nothing by mouth (NPO) after midnight for study next day&#xD;
&#xD;
      Study Day 7 (BIG DAY)&#xD;
&#xD;
        -  Awaken early (~6am) to void (still collecting 24h urine)&#xD;
&#xD;
        -  Patient returns to bed, IV catheter inserted&#xD;
&#xD;
        -  Posture Study (in morning; between 7-8am ideally)&#xD;
&#xD;
        -  Blood pressure and heart rate will be measured while supine and then while standing for&#xD;
           up to 30 minutes&#xD;
&#xD;
        -  We will draw 3 tablespoons of blood in each body position to measure hormones that&#xD;
           regulate blood pressure and blood volume&#xD;
&#xD;
        -  Hormones to verify the subject's phase of menstrual cycle&#xD;
&#xD;
        -  Serum/plasma aliquots for future analysis&#xD;
&#xD;
        -  Subjects will rate symptoms during supine period and at end of stand using Vanderbilt&#xD;
           Orthostatic Symptoms Score (VOSS)&#xD;
&#xD;
        -  Total Blood Volume (DAXOR)- using injection of iodinated I-131 tagged human serum&#xD;
           albumin nominally 25 micro-Ci of radiation blood samples drawn through IV catheter&#xD;
           before injection and for ~30 minutes post-injection (total - 25 ml)&#xD;
&#xD;
        -  This will be done after supine assessment, but before standing the subject up&#xD;
&#xD;
        -  Autonomic Function Test with Cardiac Output and Brief Tilt&#xD;
&#xD;
        -  The subject will be tilted up to 60-75 degrees head-up tilt for up to 10 minutes to&#xD;
           measure the changes in heart rate and blood pressure and symptoms with upright&#xD;
           challenge.&#xD;
&#xD;
        -  Blood volume - carbon monoxide rebreathing&#xD;
&#xD;
        -  Exercise Capacity Test (in the afternoon) Will estimate maximal oxygen consumption (VO2&#xD;
           max) This test will be conducted on a stationary bicycle. Effort will be gradually&#xD;
           increase while expired air is measured during exhaustive physical work.&#xD;
&#xD;
      All procedures are repeated at least a month later with the 2nd level of dietary salt.&#xD;
      (Randomized to high or low salt to the first phase, the second phase is the remaining level)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2021</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomization tables will be used to determine whether the 10 mEq sodium/day or 300 mEq sodium/day diet will be consumed first. Both diets will be completed on each subject (randomized crossover study), so all of the study procedures (after screening) will be repeated.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Volume</measure>
    <time_frame>after 7 days of each dietary sodium level</time_frame>
    <description>Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions. Outcome data are the absolute values for PV on Day 7 for each diet.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of Suppression of Plasma Renin Activity (From Low Sodium to High Sodium Diets)</measure>
    <time_frame>Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention</time_frame>
    <description>Whether upright plasma renin activity was modified appropriately by changes in dietary sodium in POTS &amp; healthy controls. Outcome data are the absolute values for upright plasma renin activity on Day 7 of each diet.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Magnitude of Suppression of Serum Aldosterone (From Low Sodium to High Sodium Diets)</measure>
    <time_frame>Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention</time_frame>
    <description>Whether upright serum aldosterone was modified appropriately by changes in dietary sodium in POTS patients &amp; healthy controls. Outcome data are the absolute values for upright serum aldosterone on Day 7 of each diet.</description>
  </other_outcome>
  <other_outcome>
    <measure>Magnitude of Orthostatic Tachycardia</measure>
    <time_frame>Supine and upright heart rates were measured on Day 7 of High Sodium and Low Sodium diet.</time_frame>
    <description>Whether the magnitude of the heart rate increase that occurs in patients with POTS when moving from a supine to an upright position is attenuated by a High Sodium diet relative to a Low Sodium diet.&#xD;
Heart rate was assessed after overnight rest and fasting after midnight, following at least 60 minutes of lying quietly. Heart rate was then measured at intervals after subjects had been standing for up to 30 minutes (as tolerated). Orthostatic tachycardia was calculated as the difference between standing and lying heart rates. Data are presented for 5 minutes standing (or maximal stand if &lt;5 minutes) since several patients were unable to stand for 10 minutes.&#xD;
Data in POTS patients were compared to that of Healthy Controls.</description>
  </other_outcome>
  <other_outcome>
    <measure>Upright Symptom Score</measure>
    <time_frame>Upright symptoms were assessed on the 7th day of diet.</time_frame>
    <description>Whether upright symptoms were improved in patients with POTS on a High Sodium diet relative to a Low Sodium diet.&#xD;
Patients were asked to report their standing symptom burden at the end of the Stand portion of the posture study, using the Vanderbilt Orthostatic Symptoms Scale (VOSS). They rated the severity of nine symptoms (palpitations, lightheadedness, mental confusion, blurred vision, shortness of breath, tremulousness, chest discomfort, headache, and nausea) on a scale from a minimum of 0 (reflecting an absence of symptoms) to a maximum of 10. The sum of the scores for the 9 symptoms was used to measure orthostatic symptom burden. Higher scores represent worse symptoms.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Postural Orthostatic Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>High Sodium Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Sodium Dietary Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Blood Volume</intervention_name>
    <description>we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.</description>
    <arm_group_label>High Sodium Level</arm_group_label>
    <arm_group_label>Low Sodium Dietary Level</arm_group_label>
    <other_name>carbon monoxide (CO)-red blood cell (RBC) Blood Volume</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Blood Volume</intervention_name>
    <description>Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.</description>
    <arm_group_label>High Sodium Level</arm_group_label>
    <arm_group_label>Low Sodium Dietary Level</arm_group_label>
    <other_name>DAXOR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Exercise Capacity Test - Bicycle</intervention_name>
    <description>subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.</description>
    <arm_group_label>High Sodium Level</arm_group_label>
    <arm_group_label>Low Sodium Dietary Level</arm_group_label>
    <other_name>VO2 Max (maximal oxygen consumption)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Posture Study</intervention_name>
    <description>Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.</description>
    <arm_group_label>High Sodium Level</arm_group_label>
    <arm_group_label>Low Sodium Dietary Level</arm_group_label>
    <other_name>Standing Orthostatic Challenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction&#xD;
             Center&#xD;
&#xD;
          -  Increase in heart rate â‰¥30 beats/min with position change from supine to standing (10&#xD;
             minutes)&#xD;
&#xD;
          -  Chronic symptoms consistent with POTS that are worse when upright and get better with&#xD;
             recumbence&#xD;
&#xD;
          -  Age between 18-50 years old&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Premenopausal patients with POTS and healthy volunteers&#xD;
&#xD;
          -  Only female participants are eligible.&#xD;
&#xD;
          -  Since 80-90% of POTS patients are female, and there can be differences in measures&#xD;
             with the menstrual cycle, including a small number of males might introduce a&#xD;
             significant amount of noise.&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Overt cause for postural tachycardia, i.e., acute dehydration&#xD;
&#xD;
          -  Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or&#xD;
             screening results&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or breastfeeding&#xD;
&#xD;
          -  Hypertension defined as supine resting BP&gt;145/95 mmHg off medications or needing&#xD;
             antihypertensive medication&#xD;
&#xD;
          -  Other factors which in the investigator's opinion would prevent the participant from&#xD;
             completing the protocol, including poor compliance during previous studies or an&#xD;
             unpredictable schedule&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo J Gamboa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <results_first_submitted>November 8, 2021</results_first_submitted>
  <results_first_submitted_qc>November 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">December 8, 2021</results_first_posted>
  <last_update_submitted>January 28, 2022</last_update_submitted>
  <last_update_submitted_qc>January 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Alfredo Gamboa</investigator_full_name>
    <investigator_title>Research Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>POTS</keyword>
  <keyword>Orthostatic Intolerance</keyword>
  <keyword>Orthostatic Tachycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbon Monoxide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 17, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01547117/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Healthy Participants: 17 were enrolled and randomized. 1 withdrew due to scheduling. 1 withdrew with migraines in phase 1 (low Na+). 2 withdrew in phase 1 (high Na+): 1 unable to tolerate study diet and another had difficulty cooperating with investigators.&#xD;
Postural Tachycardia Syndrome (POTS): 21 were enrolled and randomized. 6 withdrew before baseline due to age (1), pregnancy (1), prohibited meds (3), and scheduling (1). A 7th patient withdrew during phase 1 (high Na+) due to family illness.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Participants-Low Na+ Then High Na+</title>
          <description>Healthy controls were randomly assigned the order of dietary sodium (Na+) levels. After baseline labs on Day 0 and 1 day on diet with 150 milliequivalents (mEq) sodium/day, 12 participants consumed low Na+ diet (10 mEq sodium/day; LS) for 6 days followed in at least 1 month by baseline labs, 1 day of 150 mEq sodium/day and 6 days of high Na+ diet (300 mEq sodium/day; HS). All procedures were performed at both levels.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Participants-High Na+ Then Low Na+</title>
          <description>Healthy controls were randomly assigned the order of dietary sodium (Na+) levels. After baseline labs on Day 0 and 1 day on diet with 150 mEq sodium/day, 5 participants consumed high Na+ diet (300 mEq sodium/day; HS) for 6 days followed in at least 1 month by baseline labs, 1 day of 150 mEq sodium/day and 6 days of low Na+ diet (10 mEq sodium/day; LS). All procedures were performed at both levels.</description>
        </group>
        <group group_id="P3">
          <title>Patients With POTS-Low Na+ Then High Na+</title>
          <description>Patients with POTS were randomly assigned the order of dietary sodium (Na+) levels. After baseline labs on Day 0 and 1 day on diet with 150 mEq sodium/day, 10 participants consumed low Na+ diet (10 mEq sodium/day; LS) for 6 days followed in at least 1 month by baseline labs, 1 day of 150 mEq sodium/day and 6 days of high Na+ diet (300 mEq sodium/day; HS). All procedures were performed at both levels.</description>
        </group>
        <group group_id="P4">
          <title>Patients With POTS-High Na+ Then Low Na+</title>
          <description>Patients with POTS were randomly assigned the order of dietary sodium (Na+) levels. After baseline labs on Day 0 and 1 day on diet with 150 mEq sodium/day, 11 participants consumed high Na+ diet (300 mEq sodium/day; HS) for 6 days followed in at least 1 month by baseline labs, 1 day of 150 mEq sodium/day and 6 days of low Na+ diet (10 mEq sodium/day; LS). All procedures were performed at both levels.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 1 Baseline Labs</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4">1 healthy control was unable to find time to schedule study</participants>
                <participants group_id="P3" count="8">2 patients with POTS did not discontinue medication that was prohibited by protocol.</participants>
                <participants group_id="P4" count="7">1 patient with POTS did not discontinue medication that was prohibited by protocol, 1 patient was unable to find time to schedule the study, 1 was noted to be too old to participate, and 1 became pregnant between enrollment and the start of phase 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 1-150 mEq Sodium/Day</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 1-start Low Sodium or High Sodium Diet</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 1-finish</title>
              <participants_list>
                <participants group_id="P1" count="11">1 healthy control withdrew with migraines during phase 1 (low Na+).</participants>
                <participants group_id="P2" count="2">2 healthy controls withdrew during phase 1 (high Na+): 1 unable to tolerate study diet and another with difficulty cooperating with investigators..</participants>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6">1 patient with POTS withdrew during phase 1 due to a family illness.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 2-150 mEq Sodium/Day</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 2-start Low Sodium or High Sodium Diet</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Phase 2-finish</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>14 patients with Postural Tachycardia Syndrome (POTS) and 13 Controls underwent testing while on a High Sodium Diet and while on a Low Sodium Diet, administered in a randomly assigned order. Baseline data were collected prior to starting the first dietary phase.</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy Participants-Low Na+ Then High Na+</title>
          <description>Healthy controls were randomly assigned the order of dietary sodium (Na+) levels. After 1 day on diet with 150 mEq sodium/day, participants consumed low Na+ diet (10 mEq sodium/day; LS) for 6 days followed in at least 1 month by 1 day of 150 mEq sodium/day and 6 days of high Na+ diet (300 mEq sodium/day; HS). All procedures were performed at both levels.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Participants-High Na+ Then Low Na+</title>
          <description>Healthy controls were randomly assigned the order of dietary sodium (Na+) levels. After 1 day on diet with 150 mEq sodium/day, participants consumed high Na+ diet (300 mEq sodium/day; HS) for 6 days followed in at least 1 month by 1 day of 150 mEq sodium/day and 6 days of low Na+ diet (10 mEq sodium/day; LS). All procedures were performed at both levels.</description>
        </group>
        <group group_id="B3">
          <title>Patients With POTS-Low Na+ Then High Na+</title>
          <description>Patients with POTS were randomly assigned the order of dietary sodium (Na+) levels. After 1 day on diet with 150 mEq sodium/day, participants consumed low Na+ diet (10 mEq sodium/day; LS) for 6 days followed in at least 1 month by 1 day of 150 mEq sodium/day and 6 days of high Na+ diet (300 mEq sodium/day; HS). All procedures were performed at both levels.</description>
        </group>
        <group group_id="B4">
          <title>Patients With POTS-High Na+ Then Low Na+</title>
          <description>Patients with POTS were randomly assigned the order of dietary sodium (Na+) levels. After 1 day on diet with 150 mEq sodium/day, participants consumed high Na+ diet (300 mEq sodium/day; HS) for 6 days followed in at least 1 month by 1 day of 150 mEq sodium/day and 6 days of low Na+ diet (10 mEq sodium/day; LS). All procedures were performed at both levels.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="6"/>
                    <measurement group_id="B2" value="35" spread="10"/>
                    <measurement group_id="B3" value="36" spread="9"/>
                    <measurement group_id="B4" value="32" spread="6"/>
                    <measurement group_id="B5" value="33" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Volume</title>
        <description>Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions. Outcome data are the absolute values for PV on Day 7 for each diet.</description>
        <time_frame>after 7 days of each dietary sodium level</time_frame>
        <population>No data analysis for 1 healthy control who had poor venous access on Day 7 of the high sodium diet.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants Who Consumed Low Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the low sodium diet.&#xD;
Plasma Volume: Using injection of iodinated I-131 tagged human serum albumin, blood samples were drawn before and 30 minutes after injection on Day 7 of the diet.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants Who Consumed High Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the high sodium diet.&#xD;
Plasma Volume: Using injection of iodinated I-131 tagged human serum albumin, blood samples were drawn before and 30 minutes after injection on Day 7 of the diet.</description>
          </group>
          <group group_id="O3">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed Low Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the low sodium diet.&#xD;
Plasma Volume: Using injection of I-131 tagged human serum albumin, blood samples were drawn before and 30 minutes after injection on Day 7 of the diet.</description>
          </group>
          <group group_id="O4">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed High Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the high sodium diet.&#xD;
Plasma Volume: Using injection of I-131 tagged human serum albumin, blood samples were drawn before and 30 minutes after injection on Day 7 of the diet.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Volume</title>
          <description>Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions. Outcome data are the absolute values for PV on Day 7 for each diet.</description>
          <population>No data analysis for 1 healthy control who had poor venous access on Day 7 of the high sodium diet.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2805" lower_limit="2445" upper_limit="2949"/>
                    <measurement group_id="O2" value="3032" lower_limit="2620" upper_limit="3482"/>
                    <measurement group_id="O3" value="2362" lower_limit="2161" upper_limit="2715"/>
                    <measurement group_id="O4" value="2633" lower_limit="2468" upper_limit="2961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnitude of Suppression of Plasma Renin Activity (From Low Sodium to High Sodium Diets)</title>
        <description>Whether upright plasma renin activity was modified appropriately by changes in dietary sodium in POTS &amp; healthy controls. Outcome data are the absolute values for upright plasma renin activity on Day 7 of each diet.</description>
        <time_frame>Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention</time_frame>
        <population>Healthy Controls on Low Sodium diet - 1 missing blood sample; Healthy Controls on High Sodium diet - 3 missing blood samples, 2 samples with insufficient volume for analysis; POTS patients on Low Sodium diet - 1 missing blood sample; POTS patients on High Sodium diet - 2 missing blood samples</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants Who Consumed Low Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the low sodium diet.&#xD;
Upright plasma renin activity was measured in blood samples collected after up to 30 minutes of standing on the 7th day of low sodium diet.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants Who Consumed High Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the high sodium diet.&#xD;
Upright plasma renin activity was measured in blood samples collected after up to 30 minutes of standing on the 7th day of high sodium diet.</description>
          </group>
          <group group_id="O3">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed Low Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the low sodium diet.&#xD;
Upright plasma renin activity was measured in blood samples collected after up to 30 minutes of standing on the 7th day of low sodium diet.</description>
          </group>
          <group group_id="O4">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed High Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the high sodium diet.&#xD;
Upright plasma renin activity was measured in blood samples collected after up to 30 minutes of standing on the 7th day of high sodium diet.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Suppression of Plasma Renin Activity (From Low Sodium to High Sodium Diets)</title>
          <description>Whether upright plasma renin activity was modified appropriately by changes in dietary sodium in POTS &amp; healthy controls. Outcome data are the absolute values for upright plasma renin activity on Day 7 of each diet.</description>
          <population>Healthy Controls on Low Sodium diet - 1 missing blood sample; Healthy Controls on High Sodium diet - 3 missing blood samples, 2 samples with insufficient volume for analysis; POTS patients on Low Sodium diet - 1 missing blood sample; POTS patients on High Sodium diet - 2 missing blood samples</population>
          <units>ng/mL/hr</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="3.3" upper_limit="13.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit=".8" upper_limit="1.9"/>
                    <measurement group_id="O3" value="24.4" lower_limit="10.1" upper_limit="26.7"/>
                    <measurement group_id="O4" value="2.7" lower_limit=".7" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Magnitude of Suppression of Serum Aldosterone (From Low Sodium to High Sodium Diets)</title>
        <description>Whether upright serum aldosterone was modified appropriately by changes in dietary sodium in POTS patients &amp; healthy controls. Outcome data are the absolute values for upright serum aldosterone on Day 7 of each diet.</description>
        <time_frame>Upright blood samples were collected after up to 30 minutes of standing on the 7th day of each dietary sodium intervention</time_frame>
        <population>Samples were analyzed from each participant</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants Who Consumed Low Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the low sodium diet.&#xD;
Upright serum aldosterone was measured in blood samples collected after up to 30 minutes of standing on the 7th day of low sodium diet.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants Who Consumed High Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the high sodium diet.&#xD;
Upright serum aldosterone was measured in blood samples collected after up to 30 minutes of standing on the 7th day of high sodium diet.</description>
          </group>
          <group group_id="O3">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed Low Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the low sodium diet.&#xD;
Upright serum aldosterone was measured in blood samples collected after up to 30 minutes of standing on the 7th day of low sodium diet.</description>
          </group>
          <group group_id="O4">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed High Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the high sodium diet.&#xD;
Upright serum aldosterone was measured in blood samples collected after up to 30 minutes of standing on the 7th day of high sodium diet.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Suppression of Serum Aldosterone (From Low Sodium to High Sodium Diets)</title>
          <description>Whether upright serum aldosterone was modified appropriately by changes in dietary sodium in POTS patients &amp; healthy controls. Outcome data are the absolute values for upright serum aldosterone on Day 7 of each diet.</description>
          <population>Samples were analyzed from each participant</population>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="444" lower_limit="277" upper_limit="515"/>
                    <measurement group_id="O2" value="74" lower_limit="52" upper_limit="129"/>
                    <measurement group_id="O3" value="455" lower_limit="359" upper_limit="650"/>
                    <measurement group_id="O4" value="64" lower_limit="52" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Magnitude of Orthostatic Tachycardia</title>
        <description>Whether the magnitude of the heart rate increase that occurs in patients with POTS when moving from a supine to an upright position is attenuated by a High Sodium diet relative to a Low Sodium diet.&#xD;
Heart rate was assessed after overnight rest and fasting after midnight, following at least 60 minutes of lying quietly. Heart rate was then measured at intervals after subjects had been standing for up to 30 minutes (as tolerated). Orthostatic tachycardia was calculated as the difference between standing and lying heart rates. Data are presented for 5 minutes standing (or maximal stand if &lt;5 minutes) since several patients were unable to stand for 10 minutes.&#xD;
Data in POTS patients were compared to that of Healthy Controls.</description>
        <time_frame>Supine and upright heart rates were measured on Day 7 of High Sodium and Low Sodium diet.</time_frame>
        <population>Data is not included for 1 patient with POTS on a Low Sodium diet since that patient was unable to stand for even 1 minute.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants Who Consumed Low Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the low sodium diet.&#xD;
Supine and upright heart rate were measured on the 7th day of low sodium diet.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants Who Consumed High Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the high sodium diet.&#xD;
Supine and upright heart rate were measured on the 7th day of high sodium diet.</description>
          </group>
          <group group_id="O3">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed Low Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the low sodium diet.&#xD;
Supine and upright heart rate were measured on the 7th day of low sodium diet.</description>
          </group>
          <group group_id="O4">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed High Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the high sodium diet.&#xD;
Supine and upright heart rate were measured on the 7th day of high sodium diet.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of Orthostatic Tachycardia</title>
          <description>Whether the magnitude of the heart rate increase that occurs in patients with POTS when moving from a supine to an upright position is attenuated by a High Sodium diet relative to a Low Sodium diet.&#xD;
Heart rate was assessed after overnight rest and fasting after midnight, following at least 60 minutes of lying quietly. Heart rate was then measured at intervals after subjects had been standing for up to 30 minutes (as tolerated). Orthostatic tachycardia was calculated as the difference between standing and lying heart rates. Data are presented for 5 minutes standing (or maximal stand if &lt;5 minutes) since several patients were unable to stand for 10 minutes.&#xD;
Data in POTS patients were compared to that of Healthy Controls.</description>
          <population>Data is not included for 1 patient with POTS on a Low Sodium diet since that patient was unable to stand for even 1 minute.</population>
          <units>beats per minute</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="19" upper_limit="36"/>
                    <measurement group_id="O2" value="19" lower_limit="11" upper_limit="32"/>
                    <measurement group_id="O3" value="60" lower_limit="55" upper_limit="64"/>
                    <measurement group_id="O4" value="46" lower_limit="32" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Upright Symptom Score</title>
        <description>Whether upright symptoms were improved in patients with POTS on a High Sodium diet relative to a Low Sodium diet.&#xD;
Patients were asked to report their standing symptom burden at the end of the Stand portion of the posture study, using the Vanderbilt Orthostatic Symptoms Scale (VOSS). They rated the severity of nine symptoms (palpitations, lightheadedness, mental confusion, blurred vision, shortness of breath, tremulousness, chest discomfort, headache, and nausea) on a scale from a minimum of 0 (reflecting an absence of symptoms) to a maximum of 10. The sum of the scores for the 9 symptoms was used to measure orthostatic symptom burden. Higher scores represent worse symptoms.</description>
        <time_frame>Upright symptoms were assessed on the 7th day of diet.</time_frame>
        <population>Upright symptom scores were inadvertently not obtained for the following number of participants:&#xD;
Healthy Participants on Low Sodium diet: 3 Healthy Participants on High Sodium diet: 2 Patients with POTS on Low Sodium diet: 5 Patients with POTS on High Sodium diet: 6</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants Who Consumed Low Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the low sodium diet.&#xD;
Upright symptoms were assessed on the 7th day of low sodium diet.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants Who Consumed High Sodium Diet as Intervention A or Intervention B</title>
            <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the high sodium diet.&#xD;
Upright symptoms were assessed on the 7th day of high sodium diet.</description>
          </group>
          <group group_id="O3">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed Low Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the low sodium diet.&#xD;
Upright symptoms were assessed on the 7th day of low sodium diet.</description>
          </group>
          <group group_id="O4">
            <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed High Sodium Diet.</title>
            <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the high sodium diet.&#xD;
Upright symptoms were assessed on the 7th day of high sodium diet.</description>
          </group>
        </group_list>
        <measure>
          <title>Upright Symptom Score</title>
          <description>Whether upright symptoms were improved in patients with POTS on a High Sodium diet relative to a Low Sodium diet.&#xD;
Patients were asked to report their standing symptom burden at the end of the Stand portion of the posture study, using the Vanderbilt Orthostatic Symptoms Scale (VOSS). They rated the severity of nine symptoms (palpitations, lightheadedness, mental confusion, blurred vision, shortness of breath, tremulousness, chest discomfort, headache, and nausea) on a scale from a minimum of 0 (reflecting an absence of symptoms) to a maximum of 10. The sum of the scores for the 9 symptoms was used to measure orthostatic symptom burden. Higher scores represent worse symptoms.</description>
          <population>Upright symptom scores were inadvertently not obtained for the following number of participants:&#xD;
Healthy Participants on Low Sodium diet: 3 Healthy Participants on High Sodium diet: 2 Patients with POTS on Low Sodium diet: 5 Patients with POTS on High Sodium diet: 6</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="30" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="O4" value="19" lower_limit="10" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected through discharge on the last day of phase 2 of the study. This would have been Day 8 if Low Sodium diet or Day 7 if High Sodium diet.</time_frame>
      <desc>Adverse event information was collected for any untoward or unfavorable medical occurence in a participant including any abnormal sign, symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Events were self-reported by participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy Participants Who Consumed Low Sodium Diet as Intervention A or Intervention B</title>
          <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the low sodium diet.</description>
        </group>
        <group group_id="E2">
          <title>Healthy Participants Who Consumed High Sodium Diet as Intervention A or Intervention B</title>
          <description>Healthy controls were randomly assigned the order of dietary sodium levels. All procedures were performed at both levels. Results below were after the high sodium diet.</description>
        </group>
        <group group_id="E3">
          <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed Low Sodium Diet.</title>
          <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the low sodium diet.</description>
        </group>
        <group group_id="E4">
          <title>Postural Tachycardia Syndrome (POTS) Participants Who Consumed High Sodium Diet.</title>
          <description>Patients were randomly assigned the order of dietary sodium levels. Results below were after the high sodium diet.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>mass</sub_title>
                <description>Participant notified the PI that a mass had been discovered on her pineal gland during a brain MRI for another research study. We do not believe that the mass is related to any study procedures undertaken as part of this research protocol.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alfredo Gamboa, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6158751003</phone>
      <email>alfredo.gamboa@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

